NeuVasQ Biotechnologies is a spin-off founded by the Université Libre de Bruxelles (ULB). The company is developing pharmaceuticals to restore blood-brain barrier function in neurological disorders. In June 2021, NeuVasQ raised EUR 20 million in a Series A financing round led by Newton Biocapital, with participations from Theodorus IV (the ULB spin-offs investment fund), several public funding agencies (SFPI-FPIM, SRIW Life Sciences, Sambrinvest and InvestSud), and business angels from Flanders and Wallonia.